Relatively Stable SARS-CoV-2 Genome Is Good News for a Vaccine

The small number of genetic differences between the original strain of the novel coronavirus from Wuhan and those currently circulating in the US population indicates that a vaccine may likely offer lasting immunity.

Written byAmy Schleunes
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: COVERT

The genome of the novel coronavirus SARS-CoV-2 has remained relatively stable during its global spread, suggesting that a vaccine could confer long-term protection, according to The Washington Post. Although all replicating viruses accumulate some mutations that persist due to natural selection, the genetics of SARS-CoV-2 suggest that it is not mutating at a high rate, researchers report. They tell the Post that the virus’s proofreading machinery reduces both the rate of mutation and the error rate, and that no strains appear to be more dangerous than others.

There exist roughly four to 10 genetic differences between the origin virus from Wuhan and the strains currently circulating in the United States, molecular geneticist Peter Thielen of Johns Hopkins University tells the Post. “That’s a relatively small number of mutations for having passed through a large number of people,” he says. “At this point, the mutation rate of the virus ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • A former intern at The Scientist, Amy studied neurobiology at Cornell University and later earned her MFA in creative writing from the University of Iowa. She is a Los Angeles–based writer, editor, and communications strategist who collaborates on nonfiction books for Harper Collins and Houghton Mifflin Harcourt, and also teaches writing at Johns Hopkins University CTY. Her favorite projects involve sharing the insights of science and medicine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies